Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.77 |
| ▸ | GSK3A | P49840 | 2/20 | 0.77 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.67 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.65 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.65 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.65 |
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.65 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.65 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.65 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11644877 | 1.00 | ABCB1 (0.77) | ABCB1GSK3ARPS6KA3MAPK14ADORA1 | |
| SCHEMBL9501564 | 0.95 | ABCB1 (0.71) | ABCB1GSK3ARPS6KA3MAPK14ADORA1 | |
| SCHEMBL2205119 | 0.92 | NT5E (0.69) | ABCB1GSK3ARPS6KA3MAPK14ADORA1 | |
| SCHEMBL5983100 | 0.91 | ENPP1 (0.71) | ABCB1GSK3ARPS6KA3MAPK14ADORA1 | |
| SCHEMBL532929 | 0.91 | ENPP1 (0.71) | ABCB1GSK3ARPS6KA3MAPK14ADORA1 | |
| SCHEMBL5794949 | 0.91 | ENPP1 (0.71) | ABCB1GSK3ARPS6KA3MAPK14ADORA1 | |
| SCHEMBL532930 | 0.91 | ENPP1 (0.71) | ABCB1GSK3ARPS6KA3MAPK14ADORA1 | |
| SCHEMBL29169618 | 0.90 | GSK3A (0.71) | ABCB1GSK3ARPS6KA3MAPK14ADORA1 | |
| SCHEMBL14025772 | 0.90 | ABCB1 (0.77) | ABCB1GSK3ARPS6KA3MAPK14ADORA1 | |
| SCHEMBL4916919 | 0.90 | ABCB1 (0.77) | ABCB1GSK3ARPS6KA3MAPK14ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886868-A | Preparation method of 5' -DMT nucleoside compound | 天津奥瑞芙生物医药有限公司 | 2024-04-16 | — | — | CN | claimed |
| WO-2006038865-A1 | NUCLEOTIDE DERIVATIVES FOR THE TREATMENT OF TYPE 2 DIABETES AND OTHER DISORDERS | BETAGENON AB (SE) | 2006-04-13 | — | — | WO | claimed |
| EP-0876388-B1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2004-02-18 | — | — | EP | claimed |
| US-12576099-B2 | Ribose-modified cap analog and use thereof | BEIJING YOUCARE KECHUANG PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20260071217-A1 | ANTISENSE OLIGOMER COMPOUNDS | SAREPTA THERAPEUTICS, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4650358-A2 | RIBOSE-MODIFIED CAP ANALOG AND USE THEREOF | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12474327-B2 | Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1 | STALICLA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20250332189-A1 | RIBOSE-MODIFIED CAP ANALOG AND USE THEREOF | BEIJING YOUCARE KECHUANG PHARMACEUTICAL TECH CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| US-20250171779-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250171783-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-1993003052-A1 | MULTIDOMAIN DNA LIGANDS FOR PROTEIN AND NUCLEIC ACID AFFINITY CHROMATOGRAPHY AND PROCESSING OF SOLID-PHASE DNA | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0420872-A4 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES | — | 1992-10-21 | — | — | EP | disclosed |
| WO-1991010671-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1991-07-25 | — | — | WO | disclosed |
| EP-0420872-A1 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES. | UNIV TEMPLE (US) | 1991-04-10 | — | — | EP | disclosed |
| CN-1040321-A | 2 ', 5 '-therapeutic use of oligomerization adenylic acid derivant | UNIV TEMPLE (US) | 1990-03-14 | — | — | CN | disclosed |
| EP-0270651-A4 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
| EP-0121112-B1 | 2'-DEOXY-3-PHOSPHONYLMETHYL NUCLEOSIDES AND METHOD FOR THEIR PREPARATION | Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) | 1987-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576099-B2 | Ribose-modified cap analog and use thereof | RNMT, RNGTT, NSUN2 | ABCB1 2031/4885GSK3A 1157/4885RPS6KA3 116/4885 |
| US-20260071217-A1 | ANTISENSE OLIGOMER COMPOUNDS | DCLRE1B, OGG1, DCTD | ABCB1 497/4885GSK3A 2439/4885RPS6KA3 4196/4885 |
| US-20250332189-A1 | RIBOSE-MODIFIED CAP ANALOG AND USE THEREOF | RNMT, RNGTT, CPSF1 | ABCB1 2685/4885GSK3A 3051/4885RPS6KA3 274/4885 |
| US-20250171779-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | GAA, GBA3, GBA1 | ABCB1 1644/4885GSK3A 2533/4885RPS6KA3 3371/4885 |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | ABCB1 4557/4885GSK3A 2592/4885RPS6KA3 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.